Insulin resistance or metabolic syndrome occurs in conditions like obesity, type 2 diabetes, high blood pressure and high cholesterol.
Skeletal muscle cells are resistant to receive glucose needed for energy. Symptoms are fatigue and false hunger patterns due to the body is trying to obtain the glucose it needs for optimum function. ValAsta (astaxanthin) will improve glucose utilization in the muscle and brain cells which will reduce the false cravings and provide proper metabolism needed for energy. This will improve blood sugars, athletic performance and assist in maintaining a healthy weight. ValAsta can help change insulin resistant cells into more insulin sensitive cells.
Oxidative stress damages multiple cellular components including DNA, lipids, and proteins and has been linked to pathological alterations in nonalcoholic fatty liver disease (NAFLD). Reactive oxygen species (ROS) emission, resulting from nutrient overload and mitochondrial dysfunction, is thought to be a principal mediator in NAFLD progression, particularly toward the development of hepatic insulin resistance.
Click to read: An Intimate Relationship between ROS and Insulin Signaling: Implications for Antioxidant Treatment of Fatty Liver Disease